IRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues
1. IRMD estimates Q4 2024 revenue at $19.2M to $19.4M, 10%-11% year-over-year growth. 2. Full-year 2024 revenue expected between $73.1M to $73.3M, 11%-12% increase from 2023. 3. Iradimed has achieved 14 consecutive quarters of record revenue growth. 4. Strong Q4 orders indicate a robust backlog for future growth. 5. Iradimed presents at J.P. Morgan Conference, enhancing investor visibility.